Lorraine Baltzer

441 total citations
16 papers, 347 citations indexed

About

Lorraine Baltzer is a scholar working on Surgery, Oncology and Otorhinolaryngology. According to data from OpenAlex, Lorraine Baltzer has authored 16 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Oncology and 3 papers in Otorhinolaryngology. Recurrent topics in Lorraine Baltzer's work include Nausea and vomiting management (5 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Head and Neck Cancer Studies (3 papers). Lorraine Baltzer is often cited by papers focused on Nausea and vomiting management (5 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Head and Neck Cancer Studies (3 papers). Lorraine Baltzer collaborates with scholars based in United States, Mexico and France. Lorraine Baltzer's co-authors include Mark G. Kris, Leslie B. Tyson, John W. Hadden, Harvey Brandwein, Larry Schmidt, Steven M. Grunberg, William F. Hahne, Gregory T. Wolf, Declan Walsh and Charles W. Young and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Pain and Symptom Management.

In The Last Decade

Lorraine Baltzer

16 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorraine Baltzer United States	10	127	123	85	79	51	16	347
Xi-Shan Hao China	10	27 0.2×	137 1.1×	43 0.5×	165 2.1×	13 0.3×	17	377
Robert F. Berris United States	6	34 0.3×	157 1.3×	10 0.1×	49 0.6×	19 0.4×	8	345
Sun H. Lee South Korea	10	42 0.3×	82 0.7×	27 0.3×	56 0.7×	52 1.0×	19	282
Victoria Hale United States	9	31 0.2×	37 0.3×	156 1.8×	140 1.8×	64 1.3×	17	516
Paula Jiménez Fonseca Spain	11	44 0.3×	147 1.2×	11 0.1×	94 1.2×	31 0.6×	24	310
Miren Zamacona United Kingdom	9	24 0.2×	40 0.3×	123 1.4×	66 0.8×	26 0.5×	13	357
Catherine E. Thomas United Kingdom	7	67 0.5×	119 1.0×	156 1.8×	70 0.9×	38 0.7×	8	395
W Scheef Germany	10	61 0.5×	141 1.1×	12 0.1×	102 1.3×	38 0.7×	23	410
E. Heinrich Germany	6	65 0.5×	78 0.6×	28 0.3×	111 1.4×	58 1.1×	10	367
Hoon Kyo Kim South Korea	15	116 0.9×	329 2.7×	17 0.2×	163 2.1×	13 0.3×	22	641

Countries citing papers authored by Lorraine Baltzer

Since Specialization

Citations

This map shows the geographic impact of Lorraine Baltzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorraine Baltzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorraine Baltzer more than expected).

Fields of papers citing papers by Lorraine Baltzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorraine Baltzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorraine Baltzer. The network helps show where Lorraine Baltzer may publish in the future.

Co-authorship network of co-authors of Lorraine Baltzer

This figure shows the co-authorship network connecting the top 25 collaborators of Lorraine Baltzer. A scholar is included among the top collaborators of Lorraine Baltzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorraine Baltzer. Lorraine Baltzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Berinstein, Neil L., Gregory T. Wolf, Paul H. Naylor, et al.. (2011). Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunology Immunotherapy. 61(6). 771–782. 35 indexed citations

Wolf, Gregory T., Willard E. Fee, Robert W. Dolan, et al.. (2011). Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head & Neck. 33(12). 1666–1674. 44 indexed citations

Whiteside, Theresa L., Lisa H. Butterfield, Paul H. Naylor, et al.. (2011). A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunology Immunotherapy. 61(6). 783–788. 10 indexed citations

Freeman, Sara M., José Luis Franco, Daniel E. Kenady, et al.. (2010). A Phase 1 Safety Study of an IRX-2 Regimen in Patients With Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 34(2). 173–178. 25 indexed citations

Pisters, Katherine M.W., et al.. (1999). Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Supportive Care in Cancer. 7(1). 44–46. 5 indexed citations

Pizzo, Barbara, et al.. (1998). Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.. Journal of Clinical Oncology. 16(2). 771–778. 40 indexed citations

Baltzer, Lorraine, Mark G. Kris, Leslie B. Tyson, James R. Rigas, & Katherine M.W. Pisters. (1994). The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer. 73(3). 720–723. 5 indexed citations

Tyson, Leslie B., Mark G. Kris, Lorraine Baltzer, et al.. (1994). Randomized Phase II Trial Comparing Two Versus Three Doses of Ondansetron When Used in Combination with Dexamethasone in Patients Receiving Cisplatin ≥100 mg/m2. American Journal of Clinical Oncology. 17(3). 269–272. 4 indexed citations

Kris, Mark G., Steven M. Grunberg, Lorraine Baltzer, et al.. (1994). Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.. Journal of Clinical Oncology. 12(5). 1045–1049. 68 indexed citations

10.

Pisters, Katherine M.W., Mark G. Kris, Leslie B. Tyson, et al.. (1993). Midazolam in patients receiving anticancer chemotherapy and antiemetics. Journal of Pain and Symptom Management. 8(8). 519–524. 7 indexed citations

11.

Kris, Mark G., Lorraine Baltzer, Katherine M.W. Pisters, & Leslie B. Tyson. (1993). Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 72(S11). 3436–3442. 13 indexed citations

12.

Lee, Sue J., Lorraine Baltzer, Ann A. Jakubowski, et al.. (1991). Clinical pharmacology of deoxyspergualin in patients with advanced cancer.. PubMed. 51(12). 3096–101. 12 indexed citations

13.

Warrell, Raymond P., Josephia R. Muindi, Yee-Wan Stevens, et al.. (1990). Phase I clinical and pharmacological study of merbarone.. PubMed. 50(4). 1151–5. 17 indexed citations

14.

Young, Charles W., Declan Walsh, Lorraine Baltzer, et al.. (1988). Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.. PubMed. 48(24 Pt 1). 7304–9. 52 indexed citations

15.

Baltzer, Lorraine, et al.. (1984). Bone Marrow Transplantation. AJN American Journal of Nursing. 84(6). 764–764. 4 indexed citations

16.

Baltzer, Lorraine, et al.. (1984). BONE MARROW TRANSPLANTATION. AJN American Journal of Nursing. 84(6). 764–772. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact